May

Agilent Technologies (May 29, 2020)

Rhodes Technologies (May 28, 2020)

Noramco, Inc. (May 22, 2020)

Biopharmaceutical Research Company LLC (May 19, 2020)

60-Day Notice: The National Forensic Laboratory Information System Collection of Analysis Data (May 18, 2020)

30-Day Notice: Revision of a Previously Approved Collection Report of Theft or Loss of Controlled Substance; DEA Form 106 (May 18, 2020)

SpecGx LLC (May 18, 2020)

Scientific Botanical Pharmaceutical, Inc. (May 18, 2020)

Proposed Rule: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I (May 15, 2020)

Restek Corporation (May 15, 2020)

Proposed Rule: Placement of Zipeprol in Schedule I (May 14, 2020)

Isaac J. Hearne, M.D.; Decision and Order (May 7, 2020)

Purisys, LLC (May 7, 2020)

Novitium Pharma LLC (May 7, 2020)

Michael Thomas Watkins, M.D.; Decision and Order (May 7, 2020)

Almac Clinical Services Incorp. (ACSI) (May 7, 2020)

Alcami Wisconsin Corporation (May 7, 2020)

AndersonBrecon Inc. dba PCI of Illinois (May 7, 2020)

Research Triangle Institute (May 5, 2020)

Patheon API Manufacturing, Inc. (May 5, 2020)

Alcami Carolinas Corporation (May 5, 2020)

Unither Manufacturing LLC (May 5, 2020)

Absolute Standards, Inc. (May 5, 2020)

April

Kansky J. Delisma, M.D.; Decision and Order (April 29, 2020)

30-Day Notice: Contractor Drug Use Statement (April 28, 2020)

Malathy Sundaram, M.D.; Decision and Order (April 27, 2020)

Andersonbrecon, Inc, DBA PCI of Illinois (April 24, 2020)

Interim Final Rule; Reopening of Comment Period; Electronic Prescriptions for Controlled Substances (April 21, 2020)

Cedarburg Pharmaceuticals (April 21, 2020)

Sigma Aldrich Co., LLC (April 21, 2020)

United States Pharmacopeial Convention (April 20, 2020)

VHG Labs DBA LGC Standards (April 20, 2020)

Groff NA Hemplex LLC (April 20, 2020)

AMRI Rensselaer, Inc. (April 20, 2020)

Purisys, LLC (April 20, 2020)

Absolute Standards, Inc. (April 20, 2020)

AMRI Rensselaer, Inc. (April 20, 2020)

Lipomed (April 20, 2020)

Final Rule: Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance (April 17, 2020)

Denco, LLC (April 16, 2020)

Mylan Pharmaceuticals Inc. (April 16, 2020)

Final Rule: Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals (April 15, 2020)

Adjustments to Aggregate Production Quotas for Certain Schedule II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine and Pseudoephedrine for 2020, in Response to the Coronavirus Disease 2019 Public Health Emergency (April 10, 2020)

Temporary Placement of Fentanyl-Related Substances in Schedule I; Correction (April 10, 2020)

Interim Final Rule: Placement of Lemborexant in Schedule IV (April 7, 2020)

Proposed Rule: Placement of 4,4'-DMAR in Schedule I (April 7, 2020)

American Radiolabeled Chem (April 7, 2020)

Almac Clinical Services Incorp (ACSI) (April 7, 2020)

Benuvia Therapeutics Inc. (April 7, 2020)

Brewster Drug, Inc.; Decision and Order (April 3, 2020)

Gregory L. Molden, M.D.; Decision and Order (April 3, 2020)

Wildlife Laboratories, Inc. (April 1, 2020)

Shertech Laboratories, LLC (April 1, 2020)

March

Final Rule: Placement of FUB-AMB in Schedule I (March 30, 2020)

Pisgah Laboratories, Inc. (March 24, 2020)

Sharp (Bethlehem), LLC (March 24, 2020)

Cargill, Inc. (March 24, 2020)

Johnson Matthey Inc. (March 24, 2020)

Proposed Rule: Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (March 23, 2020)

John O. Dimowo, M.D.; Decision and Order (PDF) (March 19, 2020)

Siegfried USA, LLC (March 19, 2020)

Navinta LLC (March 19, 2020)

Proposed Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (March 16, 2020)

Interim Final Rule: Placement of Cenobamate in Schedule V (March 10, 2020)

Caligor Pharma Services (March 10, 2020)

SpecGx LLC (March 10, 2020)

Sigma Aldrich Research (March 10, 2020)

Siemens Healthcare Diagnostics Inc. (March 10, 2020)

William S. Husel, D.O.; Decision and Order (March 10, 2020)

Johnson Matthey Inc. (March 10, 2020)

S&B Pharma, Inc.; Correction (March 10, 2020)

Arizona Department of Corrections (March 10, 2020)

February

Proposed Rule: Registration Requirements for Narcotic Treatment Programs with Mobile Components (February 26, 2020)

Scottsdale Research Institute (February 24, 2020)

Synthcon, LLC (February 24, 2020)

Stepan Company (February 24, 2020)

Irvine Labs, Inc. (February 24, 2020)

Patheon Pharmaceuticals, Inc. (February 24, 2020)

Chemtos, LLC (February 24, 2020)

Jaime C. David, M.D.; Decision and Order (February 24, 2020)

Research Triangle Institute (February 24, 2020)

PerkinElmer, Inc. (February 24, 2020)

60-Day Notice: Contractor Drug Use Statement (February 7, 2020)

Noramco Inc. (February 3, 2020)

Spocannabis LLC (February 3, 2020)

IsoSciences, LLC (February 3, 2020)

Shelton W. Barnes, M.D.; Decision and Order (February 3, 2020)

Theresa L. Wendt, N.P.; Decision and Order (February 3, 2020)

Andrzej Kazimierz Zielke, M.D.; Decision and Order (February 3, 2020)

Kambiz Haghighi, M.D.; Decision and Order (February 3, 2020)

Solomon Adu-Beniako, M.D.; Decision and Order (February 3, 2020)

Stepan Company (February 3, 2020)

January 2020

Interim Final Rule: Placement of Lasmiditan in Schedule V (January 31, 2020)

Proposed Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl Into Schedule I (January 30, 2020)

Temporary Rule: Extension of Temporary Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (January 30, 2020)

Direct Final Rule: Additions to Listing of Exempt Chemical Mixtures (January 27, 2020)

Final Rule: Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I (January 24, 2020)

Final Rule: Removal of 6β-Naltrexol From Control (January 24, 2020)

Final Rule: Placement of Brexanolone in Schedule IV (January 24, 2020)

S&B Pharma, Inc. (January 17, 2020)

Report of Theft or Loss of Controlled Substance; DEA Form 106 (January 15, 2020)

Final Rule: Placement of Solriamfetol in Schedule IV (January 7, 2020)

December 2019

Johnson Matthey Pharmaceutical Materials Inc. (December 27, 2019)

Janssen Pharmaceuticals Inc. (December 27, 2019)

Lisa Hamilton, N.P.; Decision and Order (December 27, 2019)

Siegfried USA, LLC (December 27, 2019)

Myoderm (December 27, 2019)

Stanley Brothers Bio Tec Inc. (December 26, 2019)

Kinetochem LLC (December 26, 2019)

Royal Emerald Pharmaceuticals Research and Development (December 26, 2019)

Agronomed Pharmaceuticals (December 26, 2019)

Final Rule; Technical Correction (December 16, 2019)

Jeffrey D. Olsen, M.D.; Decision and Order (PDF) (December 16, 2019)

Meridian Medical Technologies (December 16, 2019)

Novitium Pharma LLC (December 16, 2019)

Mylan Pharmaceuticals Inc. (December 16, 2019)

DEA Supports the Use of Medication Assisted Treatment for Use Disorder: Message for DATA Waived Practitioners And Those Eligible To Become DATA Waived (PDF) (December 12, 2019)

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (December 2, 2019)